‘Made In China’ Provision Removed From Green Channel Policy
This article was originally published in PharmAsia News
The original draft of an accelerated approval policy in China for innovative devices included a condition that a product being considered for the special pathway “is produced in China.” That condition has been removed from the latest draft following pressure from the U.S. government.
You may also be interested in...
“Barriers to entry are higher than some investors appreciate, and fast followers may be on a path to permanent impairment,” industry analysts note in a recent market research report on the China opportunity for device manufacturers.
“The Gray Sheet” interviewed four China experts on the occasion of the country’s leadership transition to gauge the impact of the change on ongoing health care reforms and device purchasing.
All the planned briefs have been filed in a case, Prevor v. United States Food and Drug Administration, that could have important implications for how FDA designates a product for either device or drug primary review.